Injection Pen Market. The global injection pen market is on track for substantial growth, with a forecasted compound annual ...

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

A major news story from Sanofi this month is that "The European Medicines Agency has approved Dupixent (dupilumab) to treat ...

THOUSAND OAKS, Calif., Nov. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive top-line results from the Phase 3 WAYPOINT trial in patients with chronic ...

Get detailed information on Dupilumab, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...

Sanofi (SNY) has released an update. Sanofi’s Dupixent has received EU approval as the first treatment for children aged one to 11 with eosinophilic esophagitis, expanding its market potential ...

Approval based on phase 3 data showing significantly more children aged one to 11 years on Dupixent achieved histological disease remission at 16 weeks compared to placebo, which was sustained up to ...

French pharma major Sanofi’s (Euronext: SAN) Dupixent (dupilumab), which notched up sales of 3.5 billion euros ($3.8 billion) in third-quarter 2024, +23.8% year-on-year, has picked up yet another ...

Sanofi (SNY) has released an update. Sanofi’s Dupixent has shown promising results in a Phase 3 trial for treating chronic spontaneous urticaria, significantly reducing symptoms like itch and ...

Revenues climbed 11% to $3.72 billion, driven by growth in Eylea HD sales, profits from blockbuster asthma drug Dupixent and oncology drug Libtayo. The top line beat the Zacks Consensus Estimate ...

Immunology drug Dupixent is seeing very strong, steady growth in atopic dermatitis and asthma, and approvals continue to expend to new indications (nasal polyposis) and younger patients.